Table 2.
List of genes differentially expressed in A549 cells after CHD1L overexpression using a Cancer Drug Resistance Real-time PCR Array
| Gene | Fold change | Location | Function |
|---|---|---|---|
| Upregulated genes | |||
| ABCB1 | +3.63 | 7q21.12 | Decreases drug accumulation |
| ABCC1 | +1.25 | 16p13.11 | Involves in multi-drug resistance |
| ABCC2 | +1.00 | 10q24.2 | Involves in multi-drug resistance |
| ABCC3 | +1.02 | 17q21.33 | Involves in multi-drug resistance |
| ABCC5 | +1.01 | 3q27.1 | Provides resistance to thiopurine anticancer drugs |
| ABCG2 | +1.69 | 4q22.1 | Responses to mitoxantrone and anthracycline exposure |
| ACTB | +1.16 | 7p22.1 | Involves in cell motility, structure, integrity, and intercellular signaling |
| AHR | +1.45 | 7p21.1 | Regulate xenobiotic-metabolizing enzymes |
| AR | +2.03 | Xq12 | Encode polyglutamine and polyglycine tracts |
| ATM | +1.01 | 11q22.3 | Cell response to DNA damage |
| B2M | +1.14 | 15q21.1 | Association with the MHC |
| BCL2L1 | +1.14 | 20q11.21 | Apoptotic inhibitor |
| BLMH | +1.02 | 17q11.2 | Metabolic inactivation |
| BRCA1 | +1.13 | 17q21.31 | Maintains genomic stability |
| BRCA2 | +1.62 | 13q13.1 | Involves in maintenance of genome stability |
| CCND1 | +1.12 | 11q13.3 | Required for cell cycle G1/S transition |
| CCNE1 | +1.13 | 19q12 | Required for cell cycle G1/S transition |
| CDK2 | +1.29 | 12q13.2 | Regulates progression through the cell cycle |
| CDK4 | +1.02 | 12q14.1 | Regulates progression through the cell cycle |
| CLPTM1L | +1.67 | 5p15.33 | Increases susceptibility to cancers |
| CYP2C19 | +2.24 | 10q23.33 | Variable ability to metabolize mephenytoin |
| CYP2C8 | +1.53 | 10q23.33 | Anticonvulsive drug mephenytoin |
| CYP2E1 | +2.02 | 10q26.3 | Involves in drug metabolism |
| CYP3A5 | +1.46 | 18q21.1 | Involves in drug metabolism |
| DHFR | +1.00 | 5q14.1 | Identified on separate chromosomes |
| EGFR | +1.10 | 7p11.2 | Promotes cell proliferation |
| ELK1 | +1.25 | Xp11.23 | Promotes cell proliferation |
| ESR1 | +1.07 | 6q25.1-q25.2 | A ligand-activated transcription |
| ESR2 | +1.49 | 14q23.2-q23.3 | Inhibits cell proliferation |
| FGF2 | +1.27 | 4q28.1 | Nervous system development, wound healing, and tumor growth |
| FOS | +1.26 | 14q24.3 | Cell proliferation and transformation |
| GSTP1 | +1.02 | 11q13.2 | Reduces glutathione and detoxification |
| HPRT1 | +1.05 | Xq26.2-q26.3 | Plays a central role in the generation of purine nucleotides |
| MET | +1.40 | 7q31.2 | Induces dimerization and activation of the receptor, |
| MSH2 | +1.18 | 2p21-p16.3 | Consistent with the characteristic alterations |
| MYC | +1.31 | 8q24.21 | Participates in cell cycle progression, apoptosis and cellular transformation |
| NAT2 | +1.19 | 8p22. | Associated with higher incidences of cancer and drug toxicity |
| NFKB2 | +1.03 | 10q24.32 | Involves in inflammation and immune function |
| PPARA | +1.27 | 22q13.31 | Promotes proliferation |
| PPARG | +1.74 | 3p25.2 | A regulator of adipocyte differentiation |
| RARB | +1.64 | 3p24.2 | Mediates signaling in cell growth and differentiation |
| SULT1E1 | +2.11 | 4q13.3 | Controls levels of estrogen receptors |
| TNFRSF11A | +1.00 | 18q21.33 | Promotes proliferation |
| UGCG | +1.41 | 9q31.3 | The core structure of many glycosphingolipids |
| Downregulated genes | |||
| XPA | −1.00 | 9q22.33 | Plays a central role in nucleotide excision repair |
| ABCC1 | −1.27 | 16p13.11 | Involves in multi-drug resistance |
| AP1S1 | −1.09 | 7q22.1 | Involves in endocytosis and Golgi processing |
| APC | −1.19 | 5q22.2 | Cell migration and adhesion |
| ARNT | −1.05 | 1q21.3 | Involves in xenobiotic metabolism |
| BAX | −1.43 | 19q13.33 | Involves in P53-mediated apoptosis |
| BCL2 | −1.14 | 18q21.33 | In multiple transcript variants |
| CDKN1A | −1.10 | 6p21.2 | Interact with proliferating cell nuclear antigen, |
| CDKN1B | −1.15 | 12p13.1 | Controls the cell cycle progression |
| CDKN2A | −1.13 | 9p21.3 | Inhibits proliferation |
| CDKN2D | −1.09 | 19p13.2 | Participates in proliferation |
| CYP1A1 | −1.13 | 15q24.1 | Involves in drug metabolism |
| CYP1A2 | −1.02 | 15q24.1 | Involves in drug metabolism |
| CYP2B6 | −1.02 | 19q13.2 | Involves in drug metabolism |
| CYP2C9 | −1.23 | 10q23.33 | Involves in drug metabolism |
| CYP2D6 | −1.06 | 22q13.2 | Involves in drug metabolism |
| CYP3A4 | −1.04 | 7q22.1 | Involves in drug metabolism |
| EPHX1 | −1.25 | 1q42.12 | Activation and detoxification of epoxides |
| ERBB2 | −1.27 | 17q12 | Promotes cell proliferation |
| ERBB3 | −1.30 | 12q13.2 | Promotes cell proliferation |
| ERBB4 | −1.23 | 2q34 | Promotes cell proliferation |
| ERCC3 | −2.10 | 2q14.3 | Nucleotide excision repair |
| GAPDH | −1.08 | Xq26.2-q26.3 | Identified as a moonlighting protein |
| GSK3A | −1.07 | 19q13.2 | Regulates glycogen synthase and transcription factors |
| GSTP1 | −2.86 | 11q13.2 | Reduces glutathione and detoxification |
| HIF1A | −1.24 | 14q23.2 | Involves in energy metabolism, angiogenesis, apoptosis |
| IGF1R | −1.21 | 15q26.3 | Enhances cell survival |
| IGF2R | −1.12 | 6q25.3 | Enhances cell survival |
| MVP | −1.47 | 16p11.2 | Participates in multiple cellular processes |
| NFKB1 | −1.02 | 4q24 | Leads to cell development or delayed cell growth |
| NFKBIB | −1.07 | 19q13.2 | A transcription factor |
| NFKBIE | −1.09 | 6p21.1 | Promotes proliferation |
| PPARD | −1.89 | 6p21.31 | Inhibits the ligand-induced transcriptional activity |
| RARA | −2.78 | 17q21.2 | Implicated in regulation of development, differentiation, apoptosis |
| RARG | −1.23 | 12q13.13 | Involves in various biological processes |
| RB1 | −1.40 | 13q14.2 | A negative regulator of the cell cycle |
| RELB | −1.02 | 19q13.32 | Activation in anti-inflammatory decidual endothelial cells |
| RPLP0 | −1.27 | 12q24.23 | The functional equivalent of the E. coli L10 ribosomal protein |
| RXRA | −1.71 | 9q34.2 | Mediates the biological effects of retinoids |
| RXRB | −1.19 | 6p21.32 | Increases DNA binding |
| SOD1 | −1.10 | 21q22.11 | A homodimer to convert naturally occuring |
| TOP1 | −1.28 | 20q12 | Controls the topologic states of DNA during transcription. |
| TOP2A | −1.11 | 17q21.2 | Controls the topologic states of DNA during transcription. |
| TOP2B | −1.32 | 3p24.2 | Controls the topologic states of DNA during transcription. |
| TP53 | −1.08 | 17p13.1 | Participates in cell cycle arrest, apoptosis, senescence, DNA repair |
| TPMT | −1.19 | 6p22.3 | Correlated with variations in sensitivity and toxicity |
| XPC | −1.02 | 3p25.1 | Plays an important role in the early steps of global genome nucleotide excision repair |